Microbiomes of Pelvic Pain
Interstitial cystitis/painful bladder syndrome (IC/PBS) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) are often characterized by chronic pelvic pain with or without voiding dysfunction. IC and CP/CPPS remain an enigma within urology, with no known etiology or widely effective therapies. However, some IC and CP/CPPS patients suffer bowel co-morbidities, and it is well established that the GI tract can influence bladder function and sensation via pelvic organ crosstalk.
Like other body sites, the gut harbors a rich microflora. Studies characterizing microbial diversity and relative abundance at a particular body site, the "microbiome," reveal that microbiomes play critical roles in normal cellular and organ function, and thus this importance is emphasized with the Human Microbiome Project (HMP), an NIH Common Fund initiative. Microbiomes are also dynamic and subject to skewing, and these changes are increasingly associated with diseases including Crohn's disease, ulcerative colitis, and obesity. Antibiotic therapies alter microbiomes, often causing temporary dysfunction and sometimes resulting in diseases such as colitis. Since some IC/PBS patients have a history of urinary tract infection (UTI), they typically receive multiple courses of antibiotics. This therapeutic history of treatment may have adverse consequences for two reasons. First, potential skewing of the gut microbiome may alter normal sensory and functional homeostatic mechanisms, contributing to pain and voiding dysfunction.
Second, an altered gut microbiome may foster uropathogen reservoir expansion, and our preliminary data demonstrate urinary E. coli isolates can induce chronic pelvic pain persisting long after microbial clearance. Together these lines of reasoning raise the provocative possibility that microbiomes contribute to IC and CP/CPPS directly by supplying uropathogens or indirectly through organ crosstalk dysfunction. Therefore, is an altered gastrointestinal and/or reproductive tract microbiome associated with IC and CP/CPPS? Our team marries core NIH and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) missions, digestive diseases and kidney/urologic, to address this novel question with synergistic expertise in clinical diagnosis of IC and CP/CPPS, quantifying GI and reproductive tract microbiomes, and mechanisms of microbe-induced pelvic pain.
Chronic Pelvic Pain Syndrome
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Microbiomes of Pelvic Pain|
- Genotype Anaerobic Bacterial populations between Control patients and patients diagnosed with Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome [ Time Frame: 1 day ] [ Designated as safety issue: No ]Anaerobic bacteria will be collected from a fecal specimen from both Control patients and patients diagnosed with Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Genotyping will be done to differentiate bacterial populations between the Control patients and patients with Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Biospecimen Retention: Samples With DNA
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||January 2016|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome patients will be compared to Healthy patients.
Healthy patients will be used as controls to compare to patients diagnosed with interstitial cystitis, chronic prostatitis, or chronic pelvic pain syndrome.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01738464
|Contact: Darlene S Marko, RNemail@example.com|
|Contact: David J Klumpp, PhDfirstname.lastname@example.org|
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||David J Klumpp, PhD||Northwestern University|